Market research
P91.F PTC Therapeutics, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 2B
- P/E ratio
- Not available
- Analyst target
- 55.8
- Dividend yield
- 0.0%
- Beta
- 0.89
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US69366J2006
- Market cap
- 2B
- P/E ratio
- Not available
- Analyst target
- 55.8
- Dividend yield
- 0.0%
- Beta
- 0.89
About
About PTC Therapeutics, Inc
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the P91.F discussion.
5 years, 5 months ago
PTC Therapeutics, Inc is currently in a long term downtrend where the price is trading 17.8% below its 200 day moving average.
From a valuation standpoint, the stock is 99.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 8.5.
PTC Therapeutics, Inc's total revenue rose by 23.2% to $119M since the same quarter in the previous year.
Its net income has increased by 4.3% to $-74M since the same quarter in the previous year.
Finally, its free cash flow fell by 169.0% to $-71M since the same quarter in the previous year.
Based on the above factors, PTC Therapeutics, Inc gets an overall score of 3/5.